X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/12/08/2792998/0/en/GENFIT-Updates-2024-Outlook-Following-Acceptance-of-Elafibranor-Filings-in-Primary-Biliary-Cholangitis-PBC.html
https://www.globenewswire.com//news-release/2023/12/07/2792307/0/en/Ipsen-confirms-U-S-FDA-grants-priority-review-for-New-Drug-Application-for-elafibranor-for-the-treatment-of-rare-cholestatic-liver-disease-PBC.html
https://www.globenewswire.com//news-release/2023/11/13/2779520/0/en/Results-from-Ipsen-s-ELATIVE-pivotal-Phase-III-trial-of-elafibranor-in-PBC-presented-as-late-breaking-data-at-AASLD-congress-and-published-in-New-England-Journal-of-Medicine.html
https://www.ipsen.com/press-releases/ipsen-and-genfit-announce-positive-results-from-phase-iii-elative-trial-of-elafibranor-in-patients-with-primary-biliary-cholangitis-a-rare-cholestatic-liver-disease/
https://www.globenewswire.com/news-release/2023/06/30/2697512/0/en/Ipsen-and-GENFIT-Announce-Positive-Results-from-Phase-III-ELATIVE-trial-of-elafibranor-in-patients-with-primary-biliary-cholangitis-a-rare-cholestatic-liver-disease.html
https://www.fiercebiotech.com/biotech/ipsen-ends-2021-deal-spree-543m-biobucks-tie-up-for-genfit-s-liver-disease-drug
https://pharmaphorum.com/news/ipsen-places-e480m-bet-on-genfits-liver-drug-elafibranor/
https://www.globenewswire.com/news-release/2021/11/02/2325933/0/en/New-Clinical-Data-on-GENFIT-s-Investigational-Compound-Elafibranor-to-be-Presented-at-AASLD-The-Liver-Meeting.html
https://www.globenewswire.com/news-release/2020/09/24/2098988/0/en/GENFIT-Announces-First-Patient-First-Visit-for-ELATIVE-Phase-3-Study-Evaluating-Elafibranor-in-PBC.html#:~:text=Lille%2C%20France%3B%20Cambridge%2C%20M.A.,pivotal%2C%20Phase%203%20study%20evaluating
https://endpts.com/genfit-throws-in-the-towel-on-nash-exiting-a-tumultuous-field-full-of-bright-market-prospects-and-lethal-rd-setbacks/
https://www.biopharmadive.com/news/genfit-nash-elafibranor-negative-study-results/577721/
https://www.fiercebiotech.com/biotech/genfit-s-nash-key-phase-3-data-delayed
https://endpts.com/a-phii-flop-triggers-an-ugly-rout-for-micro-cap-biotech-aridis-genfit-ceo-passes-baton-to-successor/
https://www.fiercebiotech.com/biotech/as-genfit-hopes-to-get-its-liver-drug-market-founding-ceo-makes-way-for-new-blood
https://endpts.com/genfits-elafibranor-wins-orphan-status-for-primary-biliary-cholangitis-cidara-stock-soars-on-positive-anti-fungal-mid-stage-data/
https://endpts.com/genfit-goes-to-china-with-a-deal-worth-up-to-228m-for-nash-drug/
https://endpts.com/nash-contender-cymabay-runs-into-trouble-as-mid-stage-data-disappoint/
http://www.pmlive.com/pharma_news/genfit_claims_fda_breakthrough_status_for_liver_disease_drug_1284947
https://www.fiercebiotech.com/biotech/genfit-bags-fda-breakthrough-tag-route-to-phase-3-pbc
https://endpts.com/frances-nash-contender-genfit-leaps-onto-nasdaq-with-135m-ipo/
https://endpts.com/while-we-wait-for-nash-data-genfit-reports-positive-elafibranor-data-in-pbc-patients/
Market Place
Share 
